Seres Therapeutics (NASDAQ: MCRB) is a microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that interact with host cells and tissues to treat disease.
Seres SER-109 is the companys lead clinical candidate and…

Click here to view the original article.